Class IIITerminatedD-0577-2022
Drug recall · March 2, 2022
Bortezomib recall
Why: Failed stability specifications
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Bortezomib, 3.5 mg/vial, Single-Dose Vial, Rx Only, Mfd. By: Dr. Reddy's Laboratories Limited, Visakhapatnam - 530 046, India, NDC 43598-865-60
- Lots / codes
Lot # H210233, Exp 3/1/2023
- Quantity
- 2,980 vials
- Company
- Dr. Reddy's Laboratories, Inc., Princeton, NJ
- Distribution
- USA Nationwide
- Initiated
- January 19, 2022 · Voluntary: Firm initiated
- Classified
- February 22, 2022
- Reported
- March 2, 2022
- Ended
- December 13, 2022
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Bortezomib
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.